BACKGROUND: Currently, no pharmacological treatments for bipolar depression exist that exert rapid (within hours) antidepressant or antisuicidal effects. We previously reported that intravenous administration of the N-methyl-D-aspartate antagonist ketamine produced rapid antidepressant effects in patients with treatment-resistant bipolar depression. The present study sought to replicate this finding in an independent sample. METHODS: In this double-blind, randomized, crossover, placebo-controlled study, 15 subjects with DSM-IV bipolar I or II depression maintained on therapeutic levels of lithium or valproate received a single intravenous infusion of either ketamine hydrochloride (.5 mg/kg) or placebo on 2 test days 2 weeks apart. The primary outcome measure was the Montgomery-Asberg Depression Rating Scale, which was used to rate overall depressive symptoms at baseline; at 40, 80, 110, and 230 minutes postinfusion; and on days 1, 2, 3, 7, 10, and 14 postinfusion. RESULTS: Within 40 minutes, depressive symptoms, as well as suicidal ideation, significantly improved in subjects receiving ketamine compared with placebo (d = .89, 95% confidence interval = .61-1.16, and .98, 95% confidence interval = .64-1.33, respectively); this improvement remained significant through day 3. Seventy-nine percent of subjects responded to ketamine and 0% responded to placebo at some point during the trial. The most common side effect was dissociative symptoms, which occurred only at the 40-minute time point. CONCLUSIONS: This study replicated our previous finding that patients with bipolar depression who received a singleketamine infusion experienced a rapid and robust antidepressant response. In addition, we found that ketamine rapidly improved suicidal ideation in these patients.
RCT Entities:
BACKGROUND: Currently, no pharmacological treatments for bipolar depression exist that exert rapid (within hours) antidepressant or antisuicidal effects. We previously reported that intravenous administration of the N-methyl-D-aspartate antagonist ketamine produced rapid antidepressant effects in patients with treatment-resistant bipolar depression. The present study sought to replicate this finding in an independent sample. METHODS: In this double-blind, randomized, crossover, placebo-controlled study, 15 subjects with DSM-IV bipolar I or II depression maintained on therapeutic levels of lithium or valproate received a single intravenous infusion of either ketamine hydrochloride (.5 mg/kg) or placebo on 2 test days 2 weeks apart. The primary outcome measure was the Montgomery-Asberg Depression Rating Scale, which was used to rate overall depressive symptoms at baseline; at 40, 80, 110, and 230 minutes postinfusion; and on days 1, 2, 3, 7, 10, and 14 postinfusion. RESULTS: Within 40 minutes, depressive symptoms, as well as suicidal ideation, significantly improved in subjects receiving ketamine compared with placebo (d = .89, 95% confidence interval = .61-1.16, and .98, 95% confidence interval = .64-1.33, respectively); this improvement remained significant through day 3. Seventy-nine percent of subjects responded to ketamine and 0% responded to placebo at some point during the trial. The most common side effect was dissociative symptoms, which occurred only at the 40-minute time point. CONCLUSIONS: This study replicated our previous finding that patients with bipolar depression who received a single ketamine infusion experienced a rapid and robust antidepressant response. In addition, we found that ketamine rapidly improved suicidal ideation in these patients.
Authors: Andreas Menke; Susanne Lucae; Stefan Kloiber; Sonja Horstmann; Thomas Bettecken; Manfred Uhr; Stephan Ripke; Marcus Ising; Bertram Müller-Myhsok; Florian Holsboer; Elisabeth B Binder Journal: Am J Psychiatry Date: 2008-07 Impact factor: 18.112
Authors: Aleksandra Szczepankiewicz; Maria Skibińska; Aleksandra Suwalska; Joanna Hauser; Janusz K Rybakowski Journal: Pharmacol Rep Date: 2009 May-Jun Impact factor: 3.024
Authors: Laura E Phelps; Nancy Brutsche; Jazmin R Moral; David A Luckenbaugh; Husseini K Manji; Carlos A Zarate Journal: Biol Psychiatry Date: 2008-11-08 Impact factor: 13.382
Authors: Matthew K Nock; Irving Hwang; Nancy Sampson; Ronald C Kessler; Matthias Angermeyer; Annette Beautrais; Guilherme Borges; Evelyn Bromet; Ronny Bruffaerts; Giovanni de Girolamo; Ron de Graaf; Silvia Florescu; Oye Gureje; Josep Maria Haro; Chiyi Hu; Yueqin Huang; Elie G Karam; Norito Kawakami; Viviane Kovess; Daphna Levinson; Jose Posada-Villa; Rajesh Sagar; Toma Tomov; Maria Carmen Viana; David R Williams Journal: PLoS Med Date: 2009-08-11 Impact factor: 11.069
Authors: Lêda S B Garcia; Clarissa M Comim; Samira S Valvassori; Gislaine Z Réus; Luciana M Barbosa; Ana Cristina Andreazza; Laura Stertz; Gabriel R Fries; Elaine Cristina Gavioli; Flavio Kapczinski; João Quevedo Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2007-08-08 Impact factor: 5.067
Authors: Rodrigo Machado-Vieira; Giacomo Salvadore; David A Luckenbaugh; Husseini K Manji; Carlos A Zarate Journal: J Clin Psychiatry Date: 2008-06 Impact factor: 4.384
Authors: Sungho Maeng; Carlos A Zarate; Jing Du; Robert J Schloesser; Joseph McCammon; Guang Chen; Husseini K Manji Journal: Biol Psychiatry Date: 2007-07-23 Impact factor: 13.382
Authors: Anita E Autry; Megumi Adachi; Elena Nosyreva; Elisa S Na; Maarten F Los; Peng-fei Cheng; Ege T Kavalali; Lisa M Monteggia Journal: Nature Date: 2011-06-15 Impact factor: 49.962
Authors: Steven J Pennybaker; David A Luckenbaugh; Lawrence T Park; Craig A Marquardt; Carlos A Zarate Journal: Biol Psychiatry Date: 2017-01-22 Impact factor: 13.382
Authors: Rodrigo Machado-Vieira; Marcio G Soeiro-De-Souza; Erica M Richards; Antonio L Teixeira; Carlos A Zarate Journal: World J Biol Psychiatry Date: 2013-09-02 Impact factor: 4.132
Authors: D G Kondo; T L Hellem; X-F Shi; Y H Sung; A P Prescot; T S Kim; R S Huber; L N Forrest; P F Renshaw Journal: AJNR Am J Neuroradiol Date: 2014-02-20 Impact factor: 3.825